Jon Terrett
Head of Immuno-Oncology Research and Translation
Oncology
CRISPR Therapeutics
Switzerland
Biography
Dr. Jon Terrett has an extensive track record for discovering and progressing immuno-oncology drug candidates into the clinic. Prior to joining CRISPR Therapeutics, Jon was the Vice President of oncology discovery for CytomX, a U.S.-based biotechnology company focused on developing drugs to treat different types of cancer. In addition, Jon has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences. Jon received a B.S. in genetics at the University of Sheffield and a doctorate in genetics at the University of Nottingham.
Research Interest
Pharmaceutical Sciences
